A detailed history of Albert D Mason Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Albert D Mason Inc holds 7,172 shares of BMY stock, worth $411,170. This represents 0.29% of its overall portfolio holdings.

Number of Shares
7,172
Previous 7,172 -0.0%
Holding current value
$411,170
Previous $297,000 24.92%
% of portfolio
0.29%
Previous 0.24%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 16, 2024

SELL
$40.25 - $52.99 $1,408 - $1,854
-35 Reduced 0.49%
7,172 $297,000
Q1 2024

Apr 24, 2024

BUY
$47.98 - $54.4 $24,805 - $28,124
517 Added 7.73%
7,207 $391,000
Q3 2023

Oct 10, 2023

SELL
$57.89 - $64.73 $5,789 - $6,473
-100 Reduced 1.47%
6,690 $388,000
Q2 2023

Jul 25, 2023

SELL
$63.71 - $70.74 $62,754 - $69,678
-985 Reduced 12.67%
6,790 $434,000
Q1 2023

Apr 11, 2023

SELL
$65.71 - $74.53 $20,370 - $23,104
-310 Reduced 3.83%
7,775 $539,000
Q3 2022

Oct 12, 2022

BUY
$0.13 - $76.84 $9 - $5,378
70 Added 0.87%
8,085 $575,000
Q1 2022

Apr 20, 2022

BUY
$61.48 - $73.72 $5,840 - $7,003
95 Added 1.2%
8,015 $585,000
Q4 2021

Jan 25, 2022

BUY
$53.63 - $62.52 $138,365 - $161,301
2,580 Added 48.31%
7,920 $494,000
Q3 2021

Oct 13, 2021

BUY
$59.17 - $69.31 $9,467 - $11,089
160 Added 3.09%
5,340 $316,000
Q2 2021

Jul 14, 2021

BUY
$61.91 - $67.42 $16,406 - $17,866
265 Added 5.39%
5,180 $346,000
Q1 2021

Apr 14, 2021

BUY
$59.34 - $66.74 $16,318 - $18,353
275 Added 5.93%
4,915 $310,000
Q4 2020

Jan 12, 2021

BUY
$57.74 - $65.43 $267,913 - $303,595
4,640 New
4,640 $288,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $122B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Albert D Mason Inc Portfolio

Follow Albert D Mason Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Albert D Mason Inc, based on Form 13F filings with the SEC.

News

Stay updated on Albert D Mason Inc with notifications on news.